Coherus Confident On Avastin This Year With Humira Goal Achieved
Filing Of Adalimumab Was Slated For Q4 2020
Having delivered on a goal to file its Humira biosimilar with the FDA by the end of last year, Coherus BioSciences is now focused on getting its in-licensed bevacizumab product filing over the line, as it scans the market for further growth opportunities.
